Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Affiliations

• ¹ Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany. elias.mai@med.uni-heidelberg.de.
• ² Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ³ Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
• ⁴ Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
• ⁵ Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
• ⁶ Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
• ⁷ Department of Hematology, University Clinic Essen, Essen, Germany.
• ⁸ University Hospital Bonn, Bonn, Germany.
• ⁹ Department of Hematology and Oncology, Klinikum Baden Baden, Baden Baden, Germany.
• ¹⁰ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
• ¹¹ Department of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, Frankfurt, Germany.
• ¹² Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
• ¹³ Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
• ¹⁴ Department of Internal Medicine I, University Hospital Köln, Köln, Germany.
• ¹⁵ Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
• ¹⁶ Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Germany.